Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 8
Submit an article Journal homepage
237
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Infusion of haploidentical NKG2D-CAR-TCD45RA- cells in two pediatric patients with advanced relapsed and refractory acute leukemia was safe but achieved no clinical benefits

Adrián Fernándeza Hematological Malignancies Lab-H12O Clinical Research Unit, Spanish National Cancer Research Center (CNIO), Madrid, SpainView further author information
,
Antonio Pérez-Martínezb Pediatric Hemato-Oncology Department, La Paz University Hospital, Madrid, Spain;c Translational Research Group in Pediatric Oncology Hematopoietic Transplantation and Cell Therapy, La Paz University Hospital Institute for Health Research-IdiPAZ, Madrid, Spain;d Pediatric Department, Autonomous University of Madrid, Madrid, SpainCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-6436-9195View further author information
ORCID Icon,
Adela Escuderoe Pediatric Molecular Hemato-Oncology Department, Medical and Molecular Genetics Institute (INGEMM), La Paz University Hospital, Madrid, SpainORCID Iconhttps://orcid.org/0000-0001-8101-4014View further author information
ORCID Icon,
Isabel Mironesf Advanced Therapy Medicinal Products Production Unit, Pediatric Hemato-Oncology Service and Pharmacy Service, La Paz University Hospital, Madrid, SpainView further author information
,
Berta Gonzálezb Pediatric Hemato-Oncology Department, La Paz University Hospital, Madrid, SpainView further author information
,
Raquel de Pazg Hematology and Hemotherapy Department, La Paz University Hospital, Madrid, SpainView further author information
,
Nerea Matamalae Pediatric Molecular Hemato-Oncology Department, Medical and Molecular Genetics Institute (INGEMM), La Paz University Hospital, Madrid, SpainView further author information
,
Laura Claresc Translational Research Group in Pediatric Oncology Hematopoietic Transplantation and Cell Therapy, La Paz University Hospital Institute for Health Research-IdiPAZ, Madrid, SpainView further author information
,
Alfonso Navarroc Translational Research Group in Pediatric Oncology Hematopoietic Transplantation and Cell Therapy, La Paz University Hospital Institute for Health Research-IdiPAZ, Madrid, SpainView further author information
,
Victor Galánb Pediatric Hemato-Oncology Department, La Paz University Hospital, Madrid, SpainORCID Iconhttps://orcid.org/0000-0002-2682-9664View further author information
ORCID Icon,
Isabel Martínez-Romerab Pediatric Hemato-Oncology Department, La Paz University Hospital, Madrid, SpainView further author information
,
Joaquín Martínez-Lópeza Hematological Malignancies Lab-H12O Clinical Research Unit, Spanish National Cancer Research Center (CNIO), Madrid, Spain;h Hematology Department, 12 de Octubre University Hospital, Madrid, SpainORCID Iconhttps://orcid.org/0000-0001-7908-0063View further author information
ORCID Icon,
Alejandra Leivasa Hematological Malignancies Lab-H12O Clinical Research Unit, Spanish National Cancer Research Center (CNIO), Madrid, Spain;h Hematology Department, 12 de Octubre University Hospital, Madrid, SpainView further author information
,
Mar Valés-Gómezi Tumor Immune Activation and Evasion Group, National Biotechnology Center, Madrid, SpainView further author information
,
Cristina Ferrerasc Translational Research Group in Pediatric Oncology Hematopoietic Transplantation and Cell Therapy, La Paz University Hospital Institute for Health Research-IdiPAZ, Madrid, SpainView further author information
&
Lucía Fernándeza Hematological Malignancies Lab-H12O Clinical Research Unit, Spanish National Cancer Research Center (CNIO), Madrid, SpainView further author information
 show all
Pages 1970-1974 | Received 16 Dec 2021, Accepted 19 Mar 2022, Published online: 03 Apr 2022

References

  • Spear P, Wu MR, Sentman ML, et al. NKG2D ligands as therapeutic targets. Cancer Immun. 2013;13:8.
  • Hilpert J, Grosse-Hovest L, Grunebach F, et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol. 2012;189(3):1360–1371.
  • Salih HR, Antropius H, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003;102(4):1389–1396.
  • Baumeister SH, Murad J, Werner L, et al. Phase 1 trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma. Cancer Immunol. Res. 2018;7(1):100–112.
  • Graham C, Jozwik A, Pepper A, et al. Allogeneic CAR-T cells: more than ease of access? Cells. 2018;7(10):155.
  • Yang Y, Jacoby E, Fry TJ. Challenges and opportunities of allogeneic donor-derived CAR T cells. Curr Opin Hematol. 2015;22(6):509–515.
  • Pfefferle A, Huntington ND. You have got a fast car: chimeric antigen receptor NK cells in cancer therapy. Cancers. 2020;12:1–23,
  • Cruz CRY, Micklethwaite KP, Savoldo B, et al. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013;122(17):2965–2974.
  • Wang X, Lee DA, Wang Y, et al. Membrane-bound interleukin-21 and CD137 ligand induce functional human natural killer cells from peripheral blood mononuclear cells through STAT-3 activation. Clin Exp Immunol. 2013;172(1):104–112.
  • Chan WK, Suwannasaen D, Throm RE, et al. Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity. Leukemia. 2015;29(2):387–389.
  • Fernández L, Metais JY, Escudero A, et al. Memory T cells expressing an NKG2D-CAR efficiently target osteosarcoma cells. Clin Cancer Res. 2017;23(19):5824–5835.
  • Prenen H, Dekervel J, Hendlisz A, et al. E.V.C. Updated data from alloSHRINK phase I first-in-human study evaluating CYAD-101, an innovative non-gene edited allogeneic CAR-T in mCRC. J Clin Oncol. 2021;39(3_suppl):74–74.
  • Fernández L, Fernández A, Mirones I, et al. GMP-Compliant manufacturing of NKG2D CAR memory T cells using CliniMACS prodigy. Front Immunol. 2019;10:2361–2312.
  • Jardine L, Hambleton S, Bigley V, et al. Sensitizing primary acute lymphoblastic leukemia to natural killer cell recognition by induction of NKG2D ligands. Leuk Lymphoma. 2013;54(1):167–173.
  • Zingoni A, Vulpis E, Loconte L, et al. NKG2D ligand shedding in response to stress: role of ADAM10. Front Immunol. 2020;11:447–448.
  • Chitadze G, Bhat J, Lettau M, et al. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications. Scand J Immunol. 2013;78(2):120–129.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.